Etranacogene dezaparvovec-drlb, allows eligible adults with hemophilia B treated with the gene therapy to produce their own factor IX, which can lower risk of bleeding and reduce or eliminate the need for prophylactic treatment. In the ongoing clinical trial, the treatment reduced the rate of annual bleeds and 94 percent of patients (51 of 54) discontinued factor IX prophylaxis and remained prophylaxis-free. The most common side effects (incidence ≥5%) were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea and feeling unwell.
To read the FDA press release, please click here.